JP2023526890A - Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法 - Google Patents

Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法 Download PDF

Info

Publication number
JP2023526890A
JP2023526890A JP2022560455A JP2022560455A JP2023526890A JP 2023526890 A JP2023526890 A JP 2023526890A JP 2022560455 A JP2022560455 A JP 2022560455A JP 2022560455 A JP2022560455 A JP 2022560455A JP 2023526890 A JP2023526890 A JP 2023526890A
Authority
JP
Japan
Prior art keywords
antibody
seq
covid
patients
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526890A5 (https=
Inventor
ナイール，プラディップ
エンリケ モンテロ カシミロ，ホセ
ショー，キラン マズムダル
ブガーニ，ウシャ
ニルカンス アサリー，サンディープ
スバラマン ラマクリシュナン，メラルコード
ラモス，タニア クロンベット
モンソーン，カレット レオン
スザルテ，マイラ ラモス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of JP2023526890A publication Critical patent/JP2023526890A/ja
Publication of JP2023526890A5 publication Critical patent/JP2023526890A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022560455A 2020-04-04 2021-04-03 Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法 Pending JP2023526890A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
CUCU-2020-0027 2020-04-17
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (2)

Publication Number Publication Date
JP2023526890A true JP2023526890A (ja) 2023-06-26
JP2023526890A5 JP2023526890A5 (https=) 2024-04-12

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560455A Pending JP2023526890A (ja) 2020-04-04 2021-04-03 Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法

Country Status (15)

Country Link
US (1) US20230151107A1 (https=)
EP (1) EP4126961A4 (https=)
JP (1) JP2023526890A (https=)
KR (1) KR20220165267A (https=)
CN (1) CN115698071A (https=)
AU (1) AU2021247258A1 (https=)
BR (1) BR112022018936A2 (https=)
CA (1) CA3174566A1 (https=)
CL (1) CL2022002684A1 (https=)
CO (1) CO2022014199A2 (https=)
IL (1) IL296487A (https=)
MX (1) MX2022012229A (https=)
TW (1) TW202200202A (https=)
WO (1) WO2021199006A1 (https=)
ZA (1) ZA202210032B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
KR20110112307A (ko) * 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
CN112424226B (zh) * 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
WO2021130195A1 (en) * 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Method of treating virus infection using a tlr7 agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIN. COSMET. INVESTIG. DERMATOL., vol. 8, JPN6025036215, 2015, pages 215 - 222, ISSN: 0005676078 *
THE LANCET, vol. Vol. 395, Issue 10229, JPN6025036217, 2020, pages 1033 - 1034, ISSN: 0005676079 *

Also Published As

Publication number Publication date
EP4126961A4 (en) 2024-07-17
TW202200202A (zh) 2022-01-01
KR20220165267A (ko) 2022-12-14
MX2022012229A (es) 2022-10-27
CL2022002684A1 (es) 2023-03-24
US20230151107A1 (en) 2023-05-18
WO2021199006A1 (en) 2021-10-07
EP4126961A1 (en) 2023-02-08
ZA202210032B (en) 2024-09-25
AU2021247258A1 (en) 2022-11-10
BR112022018936A2 (pt) 2022-12-06
IL296487A (en) 2022-11-01
CN115698071A (zh) 2023-02-03
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08

Similar Documents

Publication Publication Date Title
Zhang et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
CN115605508A (zh) 用于治疗冠状病毒感染和所产生的炎症诱导的肺损伤的方法
JP2023526890A (ja) Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法
CN101466392B (zh) 用于预防或治疗hiv感染的药用组合物及其应用
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
US20200010553A1 (en) Preventive or therapeutic agent for htlv-1 associated myelopathy using low-dose of anti-ccr4 antibody
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
CN108778333A (zh) 严重社区获得性肺炎的治疗
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2025527521A (ja) 急性呼吸不全の治療
EP4137144A2 (en) Peptide for the treatment of cytokine storm syndrome
Çolak et al. Efficacy of tocilizumab in severe COVID-19: a retrospective study
TW202245799A (zh) 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法
CN116685351A (zh) Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
JP2000506839A (ja) 天然ヒトα―インターフェロンを含む薬剤組成物
RU2837859C1 (ru) Лечение коронавирусной инфекции
RU2834279C1 (ru) Пептид для лечения синдрома цитокинового шторма
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
JP2023156545A (ja) コロナウイルスによる感染症治療用の医薬組成物
JP2023156533A (ja) コロナウイルスによる感染症治療用の医薬組成物
WO2022030616A1 (ja) コロナウイルスによる感染症治療用の医薬組成物
TW202308659A (zh) 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸
WO2021202923A1 (en) Immunomodulator for the prevention and treatment of coronovirus infection and other conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250901

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260413